Tumor Biology

, Volume 32, Issue 2, pp 311–316 | Cite as

Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer

  • Iva Sedláková
  • Jaroslava Vávrová
  • Jindřich Tošner
  • Ladislav Hanousek
Research Article

Abstract

To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period. Patients with ovarian cancer had a significantly higher plasma LPA level (n = 81; median (med), 11.53 μmol/l; range, 1.78–43.21 μmol/l) compared with controls with no ovarian pathology (n = 27; med, 1.86 μmol/l; range, 0.94–9.73 μmol/l), and patients with benign ovarian tumor (n = 51; med, 6.17 μmol/l; range, 1.12–25.23 μmol/l; P < 0.001). We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics stage. The histological subtype and grade of ovarian cancer did not influence the plasma LPA levels in this study. The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of the disease.

Keywords

Ovarian carcinoma Lysophosphatidic acid Marker Diagnostics 

Notes

Acknowledgments

This project was supported by the Ministry of Health Grant Agency, No. 97373.

Conflicts of interest

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Schwartz PE, Taylor KJ. Is early detection of ovarian cancer possible? An Med. 1995;27:519–28.CrossRefGoogle Scholar
  2. 2.
    Mills GB, May C, McGill M, et al. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 1988;48:1066–71.PubMedGoogle Scholar
  3. 3.
    Fishman DA, Bozorgi K. The scientific basis of early detection of epithelial ovarian cancer: The National Ovarian Cancer Early Detection Program [NOCEDP]. Cancer Treat Res. 2002;107:3–28.PubMedGoogle Scholar
  4. 4.
    Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002;23:57–64.Google Scholar
  5. 5.
    So J, Navari J, Wang FO, Fishman DA. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynec Oncol. 2004;95:314–22.CrossRefGoogle Scholar
  6. 6.
    Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, et al. Electrospray ionization spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant versus nonmalignant ascitic fluids. Anal Biochem. 2001;290:302–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 2006;93:762–8.Google Scholar
  8. 8.
    Lee Z, Swaby FR, Liang Y, Yu S, Liu S, Lu KH, et al. Lysophophatidic Acid Is a Major Regulator of Growth-Regulated Oncogene in Ovarian Cancer. Cancer Res. 2006;66:2740–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Fujita T, Miyamoto S, Onoyama I, et al. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophopsphatidic acid in the development of human ovarian cancer. Cancer Lett. 2003;192:161–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang P, Wu X, Chen W, Liu J, Wang X. The lysophosphatidic acid [LPA] receptors their expression and significance in epithelial ovarian neoplasms. Gynec Oncol. 2007;104:714–20.CrossRefGoogle Scholar
  11. 11.
    Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatidic acid [LPA]-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res. 2000;6:2482–91.PubMedGoogle Scholar
  12. 12.
    Ozols RF, Rubin SC, Thomas G, Robboy S. Asdf. In: Hoskins WJ, Perez CA, Zouny RC, editors. Epithelial ovarian cancer. Principles and practisse of gynecologic oncology. Philadelphia: Lippincott-Raven; 1997. p. 958.Google Scholar
  13. 13.
    WHO. WHO Handbook for reporting results of cancer treatment. Geneva: WHO; 1979.Google Scholar
  14. 14.
    Sutphen R, Xu Y, Wilbanks D, Fiorica J, Grendys Jr EC, La Polla JP, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidem. 2004;13:1185–91.Google Scholar
  15. 15.
    Okita M, Gaudette DC, Mills GB, Holub BJ. Elevated levels and altered fatty acid composition of plasma lysophosphatidylicholine in ovarian cancer patients. Int J Cancer. 1997;71:31–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Yan Xu, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280:719–23.CrossRefGoogle Scholar
  17. 17.
    Sedláková I, Vávrová J, Tošner J, Hanousek L. Lysophosphatidic acid in ovarian cancer patients. Česká gynekologie. 2006;71:312–7.PubMedGoogle Scholar
  18. 18.
    Baker DL, Morrison P, Miller B, Riely CA, Tolley B, Westermann AM, et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA. 2002;287:3081–2.CrossRefPubMedGoogle Scholar
  19. 19.
    Pozlep B, Meleh M, Kobal B, et al. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors. Eur J Gynaecol Oncol. 2007;28:394–9.PubMedGoogle Scholar
  20. 20.
    So J, Wang F, Navari J, Schreher J, Fishman DA. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynec Oncol. 2005;97:870–8.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Iva Sedláková
    • 1
  • Jaroslava Vávrová
    • 2
  • Jindřich Tošner
    • 1
  • Ladislav Hanousek
    • 3
  1. 1.Department of Gynecology and ObstetricsUniversity HospitalHradec KrálovéCzech Republic
  2. 2.Department of Clinical BiochemistryUniversity HospitalHradec KrálovéCzech Republic
  3. 3.Department of Gynecology and ObstetricsHospital PardubicePardubiceCzech Republic

Personalised recommendations